Locomotor response to levodopa in fluctuating Parkinson's disease

Experimental Brain Research

Volumn 184, Issue 4, 2008, Pages 469-478

  Moore, Steven T ^a   MacDougall, Hamish G ^a,b   Gracies, Jean Michel ^a   Ondo, William G ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cadence; Gait variability; Stride length; Walking speed; Young onset

Indexed keywords

AMANTADINE; CARBIDOPA; ENTACAPONE; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GAIT; GAIT DISORDER; HUMAN; LOCOMOTION; MALE; MORNING DOSAGE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; WALKING SPEED;

ADMINISTRATION, ORAL; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; FEMALE; GAIT; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; REACTION TIME; SEVERITY OF ILLNESS INDEX;

EID: 38349153144     PISSN: 00144819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00221-007-1113-y     Document Type: Article

References (41)

1. Blin O, Ferrandez AM, Pailhous J, Serratrice G (1991) Dopa-sensitive and dopa-resistant gait parameters in Parkinson's disease. J Neurol Sci 103:51-54
2. Bloem BR, Hausdorff JM, Visser JE, Giladi N (2004) Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 19:871-884
3. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134
4. Chana P, Kuntsmann C, Reyes-Parada M, Saez-Briones P (2004) Delayed early morning turn "ON" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered. J Neurol Neurosurg Psychiatry 75:1782-1783
5. Contin M, Riva R, Martinelli P, Triggs EJ, Albani F, Baruzzi A (1996) Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology 46:1055-1058
6. Contin M, Riva R, Martinelli P, Albani F, Avoni P, Baruzzi A (2001) Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach. Ther Drug Monit 23:621-629
7. Czaja SJ, Sharit J (2003) Practically relevant research: capturing real world tasks, environments, and outcomes. Gerontologist 43(Spec No 1):9-18
8. de la Fuente-Fernandez R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, Ruth TJ, Snow BJ, Calne DB, Stoessl AJ (2000) Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 107:49-57
9. de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 49:298-303
10. Dunn W, Brown C, McGuigan A (1994) The ecology of human performance: a framework for considering the effect of context. Am J Occup Ther 48:595-607
11. Fahn S, Elton RL, Members of the UPDRS Program (1987) Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson's disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153-163
12. Hanakawa T, Fukuyama H, Katsumi Y, Honda M, Shibasaki H (1999) Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease. Ann Neurol 45:329-336
13. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL (1998) Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson's disease and Huntington's disease. Mov Disord 13:428-437
14. Hausdorff JM, Schaafsma JD, Balash Y, Bartels AL, Gurevich T, Giladi N (2003a) Impaired regulation of stride variability in Parkinson's disease subjects with freezing of gait. Exp Brain Res 149:187-194
15. Hausdorff JM, Balash J, Giladi N (2003b) Effects of cognitive challenge on gait variability in patients with Parkinson's disease. J Geriatr Psychiatry Neurol 16:53-58
16. Hirasaki E, Moore ST, Raphan T, Cohen B (1999) Effects of walking velocity on vertical head and body movements during locomotion. Exp Brain Res 127:117-130
17. Holford NH, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429-453
18. Kerrigan DC, Todd MK, Della Croce U, Lipsitz LA, Collins JJ (1998) Biomechanical gait alterations independent of speed in the healthy elderly: evidence for specific limiting impairments. Arch Phys Med Rehabil 79:317-322
19. MacDougall HG, Moore ST (2005) Marching to the beat of the same drummer: the spontaneous tempo of human locomotion. J Appl Physiol 99:1164-1173
20. MacKay-Lyons M (1998) Variability in spatiotemporal gait characteristics over the course of the l-dopa cycle in people with advanced Parkinson disease. Phys Ther 78:1083-1094
21. McColl CD, Reardon KA, Shiff M, Kempster PA (2002) Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 17:1227-1234
22. Mitchell SL, Harper DW, Lau A, Bhalla R (2000) Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology 19:100-108
23. Moore ST, MacDougall HG, Gracies J-M, Cohen H, Ondo WG (2007) Long-term monitoring of gait in Parkinson's disease. Gait Posture 26:200-207
24. Morris ME, Matyas TA, Iansek R, Summers JJ (1996) Temporal stability of gait in Parkinson's disease. Phys Ther 76:763-777 (discussion 778-780)
25. Morris ME, Huxham F, McGinley J, Dodd K, Iansek R (2001) The biomechanics and motor control of gait in Parkinson disease. Clin Biomech (Bristol, Avon) 16:459-470
26. Muller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O (2006) Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 29:61-67
27. Nutt JG (1987) Off-on phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 22:535-540
28. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The "off-on" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 310:483-488
29. Ondo W (2003) Investigational pharmacological treatments for Parkinson's diesease. In: Pahwa R, Lyons K, Koller W (eds) Handbook of Parkinson's disease. Marcel Dekker, New York
30. Ostrosky KM, VanSwearingen JM, Burdett RG, Gee Z (1994) A comparison of gait characteristics in young and old subjects. Phys Ther 74:637-644 (discussion 644-636)
31. O'Sullivan JD, Said CM, Dillon LC, Hoffman M, Hughes AJ (1998) Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function. Mov Disord 13:900-906
32. Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson's disease. Mov Disord 2:73-91
33. Schaafsma JD, Giladi N, Balash Y, Bartels AL, Gurevich T, Hausdorff JM (2003) Gait dynamics in Parkinson's disease: relationship to Parkinsonian features, falls and response to levodopa. J Neurol Sci 212:47-53
34. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N (1998) Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov Disord 13:885-894
35. Shannon KM (2004) Rating scales. In: Ebaidi M, Pfeiffer RF (eds) Parkinson's disease. CRC Press, Boca Raton, pp 663-675
36. Siegel KL, Metman LV (2000) Effects of bilateral posteroventral pallidotomy on gait of subjects with Parkinson disease. Arch Neurol 57:198-204
37. Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J (2004) Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 24:869-876
38. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J (2006) Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129:1050-1058
39. Teasdale N, Stelmach GE (1988) Movement disorders: the importance of the movement context. J Mot Behav 20:186-191
40. Vokaer M, Azar NA, de Beyl DZ (2003) Effects of levodopa on upper limb mobility and gait in Parkinson's disease. J Neurol Neurosurg Psychiatry 74:1304-1307
41. Yekutiel MP (1993) Patients' fall records as an aid in designing and assessing therapy in Parkinsonism. Disabil Rehabil 15:189-193